BioLife Solutions (NASDAQ:BLFS) Issues Quarterly Earnings Results, Beats Estimates By $0.32 EPS

BioLife Solutions (NASDAQ:BLFS) posted its quarterly earnings results on Monday. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32, RTT News reports. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same period in the prior year, the company posted ($0.21) earnings per share. BioLife Solutions updated its FY 2025 guidance to EPS.

BioLife Solutions Stock Up 2.1 %

BLFS stock opened at $24.51 on Tuesday. The company’s 50 day simple moving average is $26.74 and its 200-day simple moving average is $25.50. The firm has a market capitalization of $1.14 billion, a PE ratio of -23.12 and a beta of 1.91. BioLife Solutions has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

Analysts Set New Price Targets

Several research analysts recently issued reports on BLFS shares. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. Craig Hallum increased their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. KeyCorp upped their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. TD Cowen upped their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $29.43.

Insider Activity

In other news, CFO Troy Wichterman sold 987 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,009 shares of company stock worth $272,594 over the last ninety days. 2.20% of the stock is currently owned by insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.